AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01391845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo orally in a unique dose the day of hCG injection
Study NCT01391845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: ulipristal acetate 30mg orally in a unique dose the day of hCG administration
Study NCT03766139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUPERCELL GLUE
Description: Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
Study NCT03766139 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRFM ALONE
Description: Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
Study NCT01032460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubate with the macintosh laryngoscope
Description: intubate with the macintosh laryngoscope
Study NCT01032460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubate with the C-MAC laryngoscope
Description: intubate with the C-MAC laryngoscope
Study NCT01032460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubate with the Airtraq device
Description: intubate with the Airtraq device
Study NCT01921231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Prilocaine 1%
Description: Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
Study NCT01921231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5%
Description: Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
Study NCT02215668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Exercise muscle stretching and body warming.
Study NCT02215668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Exercise muscle stretching and body warming.
Study NCT02203617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Content/Pediatric Anticipatory Guidance
Description: educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
Study NCT02573168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
Study NCT02040948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: - Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)
Study NCT01115569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate
Description: Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
Study NCT03132792 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified AFPᶜ³³²T cells
Description: Infusion of autologous genetically modified AFPᶜ³³²T cells
Study NCT01831973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Study NCT03023644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Description: Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
Study NCT01507610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
Study NCT02391246 — intervention group
Intervention type: OTHER
Intervention: Positron Emission Tomography Imaging
Description: Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
Study NCT02203617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book provision
Description: Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
Study NCT02203617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book provision
Description: Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
Study NCT02176668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 100
Description: The number of times : multiple-dose Rout : oral administration
Study NCT01286415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy-Cognitive Only
Description: Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
Study NCT01286415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Present Centered Therapy
Description: Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
Study NCT04036162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: MagnetoEncephaloGraphy (MEG) records
Study NCT00569946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops.
Study NCT03893591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti Xa levels
Description: one Blood sample
Study NCT00762463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: capsule, 200 mg QD, 6-12 weeks
Study NCT00762463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac SR
Description: tablet, 75 mg QD,6-12 weeks
Study NCT04473950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naloxone Hydrochloride
Description: An intramuscular (IM) injection of naloxone will be given.
Study NCT04473950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Hydrochloride
Description: An intramuscular (IM) injection of naloxone will be given.
Study NCT04473950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An IM injection of 0.9% normal saline will be given.
Study NCT04473950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An IM injection of 0.9% normal saline will be given.
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: d1 Irinotecan 180mg/m² every two weeks
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study NCT01507610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
Study NCT01032512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SUPPORTAN + GLUTAMINE PLUS
Description: 600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
Study NCT01032512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: NO PREOPERATIVE NUTRITION SUPPORT
Description: Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
Study NCT02689336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02689336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT03229759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidine Dihydrocloride in aqueous solution
Description: application of investigational product
Study NCT03229759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: application of vehicle control
Study NCT03229759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Control
Description: application of placebo
Study NCT01146067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Rivastigmine capsules 1.5 mg
Study NCT01146067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine capsules 1.5 mg
Study NCT02176668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration
Study NCT02176668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 200
Description: The number of times : multiple-dose Rout : oral administration
Study NCT02176668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 400
Description: The number of times : multiple-dose Rout : oral administration
Study NCT01454440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
Study NCT01717911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
Study NCT01717911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
Study NCT01717911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
Study NCT02980783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT®™ with Lidocaine
Description: Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
Study NCT01454440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eptifibatide
Description: Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
Study NCT02882269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
Study NCT02882269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
Study NCT02013531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
Study NCT01314768 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention
Description: Structured behavioural Brief intervention given by trained GPs
Study NCT01314768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Business as usual
Description: GPs to treat patient as they have until now based on best established practice
Study NCT01314768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening and outcome evaluation only
Description: No additional intervention
Study NCT00774943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 557
Description: A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
Study NCT00774943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 557
Description: A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
Study NCT00880542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
Study NCT00880542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
Study NCT00910026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low tidal volume ventilation
Description: 6 ml/kg tidal volume ventilation
Study NCT00910026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high tidal volume ventilation
Description: 12 ml/kg tidal volume ventilation
Study NCT02371148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib-Rituximab-Bendamustine
Description: Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8
Study NCT04213417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath therapy and Matrix Rhythm Therapy
Description: MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
Study NCT04213417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath therapy
Description: Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
Study NCT02501226 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
Study NCT02501226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENVIE psychoeducational program
Description: The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference.
Study NCT02470832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: d1-2 5-FU 2200 mg/m² every two weeks
Study NCT02470832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Study NCT02646657 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vedolizumab 300 mg
Description: Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
Study NCT03727269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Fit Training Experimental Group
Description: Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
Study NCT03727269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities
Study NCT03755089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine
Description: 200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
Study NCT03755089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: 30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure